Status:
COMPLETED
Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
Lead Sponsor:
Pfizer
Conditions:
Hepatitis, Chronic
Hepatitis C Virus
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.
Eligibility Criteria
Inclusion
- HCV Positive With HCV RNA\>100,000 iu/ml Genotype 1; COHORT A- non responders or partial
Exclusion
- HIV HBV co-infection Decompensated liver disease Liver disease due to causes other than HCV, AFP\>200ng/ml
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00671671
Start Date
April 1 2008
End Date
December 1 2008
Last Update
January 14 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Gainesville, Florida, United States, 32608